Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI)

The prospective multi-center ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a Diffuse Optical Spectroscopic Imaging (DOSI)-derived imaging endpoint, the Tissue Optical Index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Tromberg, Bruce J., Zhang, Zheng, Leproux, Anaïs, O’Sullivan, Thomas D., Cerussi, Albert E., Carpenter, Philip, Mehta, Rita S., Roblyer, Darren, Yang, Wei, Paulsen, Keith D., Pogue, Brian W., Jiang, Shudong, Kaufman, Peter, Yodh AG, Arjun G., Chung, So Hyun, Schnall, Mitchell, Snyder, Bradley S., Hylton, Nola, Boas, David A., Carp, Stefan A., Isakoff, Steven J., Mankoff, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5148152/
https://ncbi.nlm.nih.gov/pubmed/27527559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados